

# 2820/9820

## Global X China Biotech ETF

Category: Thematic Growth  
As of 30/09/2024



### IMPORTANT INFORMATION

Investors should not base investment decisions on this document alone. Please refer to the Prospectus for details including the product features and the risk factors. Investment involves risks. There is no guarantee of the repayment of the principal. Investors should note:

- Global X China Biotech ETF's (the "Fund's") investment in equity securities is subject to general market risks, whose value may fluctuate due to various factors, such as changes in investment sentiment, political and economic conditions and issuer-specific factors.
- Biotech companies invest heavily in research and development which may not necessarily lead to commercially successful products, and the ability for biotech companies to obtain regulatory approval (for example, product approval) may be long and costly.
- China is an emerging market. The Fund invests in Chinese companies which may involve increased risks and special considerations not typically associated with investments in more developed markets, such as liquidity risk, currency risks, political risk, legal and taxation risks, and the likelihood of a high degree of volatility.
- The trading price of the Fund's unit (the "Unit") on the Stock Exchange of Hong Kong is driven by market factors such as demand and supply of the Unit. Therefore, the Units may trade at a substantial premium or discount to the Fund's net asset value.
- The Fund's synthetic replication strategy will involve investing up to 50% of its net asset value in financial derivative instruments ("FDIs"), mainly funded total return swap transaction(s) through one or more counterparty(ies). Risks associated with FDIs include counterparty/credit risk, liquidity risk, valuation risk, volatility risk and over-the-counter transaction risk. FDIs are susceptible to price fluctuations and higher volatility, and may have large bid and offer spreads and no active secondary markets. The leverage element/component of an FDI can result in a loss significantly greater than the amount invested in the FDI by the Sub-Fund.
- As part of the securities lending transactions, there is a risk of shortfall of collateral value due to inaccurate pricing of the securities lent or change of value of securities lent. This may cause significant losses to the Fund. The borrower may fail to return the securities in a timely manner or at all. The Fund may suffer from a loss or delay when recovering the securities lent out. This may restrict the Fund's ability in meeting delivery or payment obligations from realisation requests.

### INVESTMENT OBJECTIVES

The Fund is a passive ETF and seeks to provide investment results that, before deduction of fees and expenses, closely correspond to the performance of the Solactive China Biotech Index NTR (the "Index").

### FUND DETAILS

Listing Date	25/07/19
Index	Solactive China Biotech Index NTR
Stock Code (HKD/USD)	2820/9820
Number of Holdings	30
NAV per Unit	RMB47.31
Assets Under Management	USD 50.72 million
TD Rolling 1 Yr	-0.65%
TE Rolling 1 Yr	0.13%
Ongoing Charges Over a Year*	0.68%
Board Lot Size	50 Units
Dividend Policy	Annually (if any)
Exchange	SEHK
ISIN	HK0000516697 (HKD)/ HK0000516689 (USD)

### PERFORMANCE (%)

CUMULATIVE RETURN	NAV (%)	INDEX (%)
1 Mth	21.87	22.04
3 Mths	21.39	21.84
6 Mths	11.61	12.08
YTD	-8.69	-8.16
Since Listing	-6.17	-2.08

### ANNUALISED RETURN

1 Yr	-9.80	-9.15
3 Yrs	-20.83	-20.25
5 Yrs	-2.42	-1.59
Since Listing	-1.22	-0.40

### CALENDAR YEAR RETURN

2023	-12.92	-12.32
2022	-26.09	-25.52
2021	-19.65	-19.17
2020	69.70	71.88
2019	-	-

Source: Mirae Asset Global Investments (Hong Kong) Limited, data as of 30 September 2024. All performance figures of the Fund are net of fees, NAV to NAV, in RMB. Where no past performance figures are shown there was insufficient data available in that year to provide performance figures.

### TOP 10 HOLDINGS (%)

WuXi AppTec Co., Ltd. Class A	10.19
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A	9.58
Wuxi Biologics (Cayman) Inc.	9.50
Innovent Biologics, Inc.	8.47
Shanghai RAAS Blood Products Co., Ltd. Class A	5.51
Akeso, Inc.	5.27
Sino Biopharmaceutical Limited	5.15
Beijing Tiantan Biological Products Corporation Limited Class A	3.88
Hansoh Pharmaceutical Group Company Limited	3.35
Walvax Biotechnology Co., Ltd. Class A	3.22

### INDUSTRY BREAKDOWN (%)

Biotechnology	41.88	Health Care Providers & Services	1.25
Pharmaceuticals	33.08	Cash	0.09
Life Sciences Tools & Services	23.69		

\* Please refer to the Fund's offering document for further details (including fees).

Certain information contained in this document is compiled from third party sources. Whilst Mirae Asset Global Investments (Hong Kong) Limited ("Mirae Asset HK"), the Manager of the Fund, has, to the best of its endeavor, ensured that such information is accurate, complete and up-to-date, and has taken care in accurately reproducing the information, Mirae Asset HK accepts no liability for any loss or damage of any kind resulting out of the unauthorized use of this document. The information contained in this document is for information purposes only and does not constitute any recommendation, offer or solicitation to buy, sell or subscribe to any securities or financial instruments in any jurisdiction. Investment involves risk. It cannot be guaranteed that the performance of the Fund will generate a return and there may be circumstances where no return is generated or the amount invested is lost. Past performance is not indicative of future performance. Before making any investment decision to invest in the Fund, investors should read the Fund's Prospectus for details and the risk factors. Investors should ensure they fully understand the risks associated with the Fund and should also consider their own investment objective and risk tolerance level. Investors are advised to seek independent professional advice before making any investments. The Fund's Prospectus is available on the website [www.globalxetfs.com](http://www.globalxetfs.com).

References to particular sectors, securities or companies are for general information and illustrative purposes only and are not recommendations to buy or sell a security, or an indication of the issuer's holdings at any one time. Investors should note that the Fund differs from a typical retail fund as Units may only be created and realized by participating dealers in large unit sizes. This document is issued by Mirae Asset HK and has not been reviewed by the Securities and Futures Commission of Hong Kong. Please read the disclaimer in relation to the Index in the Fund's Prospectus.